港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

映恩生物-B

207.400

-7.000-3.26%

成交量：23.77万

成交额：4,990.51万

市值：177.20亿

市盈率：-1.48

高：218.800

开：216.000

低：206.800

收：214.400

数据加载中...

总览公司新闻公告

映恩生物上市首日涨超110%，每手赚上万港元董事会主席朱忠远：虽三四年未融资，但是公司现金越来越多

每日经济新闻

映恩生物首日暴涨116%：从“破发潮”到大涨，港股18A企业现反转信号

映恩生物暴涨116%，赛诺菲、BMS新药研究折戟

医药经济报

港股收盘(04.15) | 恒指收涨0.23% 大消费股表现活跃映恩生物-B(09606)首挂飙升116%

【新股IPO】映恩生物(09606)首挂收报205港元较招股价高116.7%

映恩生物在港交所挂牌上市

港股收盘，恒指收涨0.23%，恒生科技指数收跌0.67%，映恩生物(09606.HK)上市首日收涨116.70%，中芯国

映恩生物正式挂牌港交所

映恩生物，成功在香港上市，早盘大涨逾1.27倍

港股午评：恒指横盘震荡调整食品饮料等消费板块表现亮眼

港股午评|恒生指数早盘涨0.19% 食品饮料股走高

午评：港股恒指涨0.19% 科指跌0.91% 映恩生物涨超127%

【新股IPO】映恩生物(09606) 布局ADC领域全球化商业模式首日盘中暴涨

医健IPO解码｜从“魔法子弹”到资本新宠，映恩生物能否穿越市场周期？

21世纪经济报道

映恩生物港股上市募资15亿港元加速创新抗体药物研发

ADC明星企业映恩生物登陆港交所，盘中涨幅高达116.7%

暴涨130%！映恩生物正式登陆港交所，市值超181亿港元，抗体偶联药物ADC领域全球领跑者

新股首日 | 映恩生物-B涨幅扩大至130%，一手赚超12500港元

老虎资讯综合

映恩生物-B首挂上市早盘高开逾115%

异动解读 | 映恩生物上市首日大涨114%，ADC创新药研发引爆投资热潮

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/09606/news?page=2"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"09606","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09606\",,,,,undefined,":{"symbol":"09606","market":"HK","secType":"STK","nameCN":"映恩生物-B","latestPrice":207.4,"timestamp":1746000497038,"preClose":214.4,"halted":0,"volume":237685,"delay":0,"floatShares":85436500,"shares":85436464,"eps":-139.94669746245498,"marketStatus":"未开盘","change":-7,"latestTime":"04-30 16:08:17","open":216,"high":218.8,"low":206.8,"amount":49905064,"amplitude":0.05597,"askPrice":207.4,"askSize":200,"bidPrice":207,"bidSize":600,"shortable":0,"etf":0,"ttmEps":-139.94670812065593,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1746149400000},"marketStatusCode":0,"adr":0,"listingDate":1744646400000,"exchange":"SEHK","adjPreClose":214.4,"openAndCloseTimeList":[[1745976600000,1745985600000],[1745989200000,1746000000000]],"volumeRatio":0.3775980768748601,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09606\",,,,,undefined,":{"symbol":"09606","floatShares":85436500,"roa":"-6.51%","roe":"--","lyrEps":-139.946708,"volumeRatio":0.3775980768748601,"shares":85436464,"dividePrice":0,"high":218.8,"amplitude":0.05597,"preClose":214.4,"low":206.8,"week52Low":178.8,"pbRate":"-8.20","psRate":"8.56","week52High":234.6,"institutionHeld":0,"latestPrice":207.4,"committee":0.5,"eps":-139.94669746245498,"divideRate":0,"volume":237685,"delay":0,"ttmEps":-139.94670812065593,"open":216,"prevYearClose":94.6,"prevWeekClose":207.4,"prevMonthClose":207.4,"prevQuarterClose":94.6,"fiveDayClose":218.6,"twentyDayClose":94.6,"sixtyDayClose":94.6},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09606\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2527419596","title":"映恩生物上市首日涨超110%，每手赚上万港元 董事会主席朱忠远：虽三四年未融资，但是公司现金越来越多","url":"https://stock-news.laohu8.com/highlight/detail?id=2527419596","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527419596?lang=zh_cn&edition=fundamental","pubTime":"2025-04-15 20:46","pubTimestamp":1744721219,"startTime":"0","endTime":"0","summary":"4月15日，映恩生物-B（HK09606，股价205港元，市值175.1亿港元）在港交所挂牌上市，这是港交所2022年以来融资规模最大的“18A”生物科技上市公司（指适用港交所上市规则第18A章的公司）。映恩生物每股定价94.6港元，共发行1733.23万股。上市首日开盘后，映恩生物一路走高，盘中最高涨幅曾超过130%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202504153377600285.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"5297752f2e4ee415e69380642a004984","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504153377600285.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09606"],"gpt_icon":1},{"id":"2527195974","title":"映恩生物首日暴涨116%：从“破发潮”到大涨，港股18A企业现反转信号","url":"https://stock-news.laohu8.com/highlight/detail?id=2527195974","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527195974?lang=zh_cn&edition=fundamental","pubTime":"2025-04-15 20:44","pubTimestamp":1744721065,"startTime":"0","endTime":"0","summary":"尽管市场走势疲软，但ADC（抗体偶联药物）龙头企业映恩生物(09606.HK)上市首日仍然大涨。4月15日，映恩生物(09606.HK)在港交所主板挂牌上市，当天报收于205港元，首日涨幅超过116%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202504153377599531.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"5297752f2e4ee415e69380642a004984","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504153377599531.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["YANG","HSTECH","09606","BK4614"],"gpt_icon":1},{"id":"2527428573","title":"映恩生物暴涨116%，赛诺菲、BMS新药研究折戟","url":"https://stock-news.laohu8.com/highlight/detail?id=2527428573","media":"医药经济报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527428573?lang=zh_cn&edition=fundamental","pubTime":"2025-04-15 19:34","pubTimestamp":1744716855,"startTime":"0","endTime":"0","summary":"映恩生物正式登陆港交所4月15日，ADC明星企业映恩生物正式登陆港交所，全球发售股份定价为每股94.6港元，开盘价为181港元，截至收盘，映恩生物每股报205港元，大涨116%，总市值约170.5亿港元。截至目前，映恩生物尚未获得任何候选药物的上市批准，亦未从产品销售中获得任何收入。BMS此前预计，如果Ⅲ期试验成功，Camzyos有望在2026年获批新适应症，并在2029年实现40亿美元的峰值销售额。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250415194521a6bb2c13&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250415194521a6bb2c13&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09606"],"gpt_icon":1},{"id":"2527463916","title":"港股收盘(04.15) | 恒指收涨0.23% 大消费股表现活跃 映恩生物-B(09606)首挂飙升116%","url":"https://stock-news.laohu8.com/highlight/detail?id=2527463916","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527463916?lang=zh_cn&edition=fundamental","pubTime":"2025-04-15 16:39","pubTimestamp":1744706361,"startTime":"0","endTime":"0","summary":"截止收盘，恒生指数涨0.23%或48.87点，报21466.27点，全日成交额1850.64亿港元；恒生国企指数涨0.21%，报7982.88点；恒生科技指数跌0.67%，报4981.6点。截至收盘，跌4.53%，报45.35港元，成交额62.32亿港元，拖累恒指15.99点。美国特朗普政府正以威胁国家安全为由，启动对半导体和药品进口的调查。热门异动股1. 映恩生物-B首挂上市。截至收盘，涨4.57%，报70.9港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1278832.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00027","LU1880383366.USD","02833","LU0607220059.USD","LU0488056044.USD","LU0211977185.USD","LU0140636845.USD","BK1604","LU0173614495.USD","MCHmain","LU0307460666.USD","01918","LU1048596156.SGD","BK1504","01478","BK1589","LU1166156734.SGD","BK1549","LU2039709279.SGD","LU0594300419.USD","01458","HSTECH","BK1526","LU0149534421.HKD","LU0650527681.SGD","HHImain","LU0348783233.USD","YANG","LU0588546209.SGD","513600","BK4614","BK1523","LU0384037296.USD","LU0821914370.USD","BK1240","000997.SH","BK1172","IE0034224299.USD","LU1328615791.USD","LU0593848301.USD","LU0348784397.USD","BK1555","HSI","09606","LU0737861699.HKD","BK1607","LU1224709979.USD"],"gpt_icon":1},{"id":"2527345054","title":"【新股IPO】映恩生物(09606)首挂收报205港元 较招股价高116.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2527345054","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527345054?lang=zh_cn&edition=fundamental","pubTime":"2025-04-15 16:14","pubTimestamp":1744704881,"startTime":"0","endTime":"0","summary":"金吾财讯 | 映恩生物(09606)首挂收报205港元，较招股价高116.7%，全日成交1082.52万股，成交额20.3亿港元，不计手续费，每手100股，账面赚11040港元。该股早盘开报181港元，较招股价高91.33%，亦为全日低点，最高见222港元。最新总市值170.51亿港元。","market":"hk","thumbnail":"https://static.szfiu.com/news/20220324/M2U4NDlhMmZjNTFjY2Q0M2EzMzMyMTg5Mjc0MzM=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20220324/M2U4NDlhMmZjNTFjY2Q0M2EzMzMyMTg5Mjc0MzM=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1957245","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"gpt_icon":0},{"id":"2527566450","title":"映恩生物在港交所挂牌上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2527566450","media":"新华财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527566450?lang=zh_cn&edition=fundamental","pubTime":"2025-04-15 16:11","pubTimestamp":1744704683,"startTime":"0","endTime":"0","summary":"新华财经香港4月15日电（记者林迎楠）4月15日，创新生物制药公司映恩生物正式在香港联合交易所主板挂牌上市。上市首日，开市价已较招股价94.6元高出超过90%。截至午间休市，映恩生物报214.80港元／股，涨127.06%，总市值约178.66亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"5297752f2e4ee415e69380642a004984","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504153377352875.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09606"],"gpt_icon":1},{"id":"2527452883","title":"港股收盘，恒指收涨0.23%，恒生科技指数收跌0.67%，映恩生物(09606.HK)上市首日收涨116.70%，中芯国","url":"https://stock-news.laohu8.com/highlight/detail?id=2527452883","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527452883?lang=zh_cn&edition=fundamental","pubTime":"2025-04-15 16:08","pubTimestamp":1744704527,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"5297752f2e4ee415e69380642a004984","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["HSI","LU2148510915.USD","BK1526","LU1064131003.USD","MHImain","LU1064130708.USD","HHImain","02833","09606","BK0214","07226","BK1614","688981","BK1163","HSTECH","SGXZ81163826.USD","YANG","BK4614","BK1607","MCHmain","HSCEI","00981","SGXZ49509284.SGD","513600","HSImain","BK1610"],"gpt_icon":0},{"id":"2527285744","title":"映恩生物正式挂牌港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2527285744","media":"金融界","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527285744?lang=zh_cn&edition=fundamental","pubTime":"2025-04-15 15:08","pubTimestamp":1744700897,"startTime":"0","endTime":"0","summary":"观点网讯：4月15日，映恩生物Duality Biotherapeutics, Inc.在香港联合交易所主板成功挂牌上市。映恩生物此次招股公开发售部分获115.14倍认购，国际发售部分获13.52倍认购。映恩生物此次IPO引入15名基石投资者，合共认购534.18万股发售股份，包括BioNTech、LAV Star等。截至最后实际可行日期，映恩生物在17个国家的230多个临床试验中心拥有七项全球多区域临床试验，已有2,000多名患者入组。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041515122497384778&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041515122497384778&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09606"],"gpt_icon":1},{"id":"2527436668","title":"映恩生物，成功在香港上市，早盘大涨逾1.27倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2527436668","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527436668?lang=zh_cn&edition=fundamental","pubTime":"2025-04-15 13:05","pubTimestamp":1744693500,"startTime":"0","endTime":"0","summary":"　　2025年4月15日，映恩生物Duality Biotherapeutics, Inc.，成功在香港联合交易所主板挂牌上市。　　映恩生物是次IPO全球发售1733.23万股H股，占发行完成后总股份的20.29%，每股下限定价94.60港元，募集资金总额约16.40亿港元，所得款净额约15.13亿港元。　　映恩生物是次招股公开发售部分获115.14倍认购，国际发售部分获13.52倍认购。　　截至午间收市，映恩生物每股报214.80港元，大涨127.06%，总市值约178.66亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-04-15/doc-inetfnxu8468291.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09606"],"gpt_icon":1},{"id":"2527484547","title":"港股午评：恒指横盘震荡调整 食品饮料等消费板块表现亮眼","url":"https://stock-news.laohu8.com/highlight/detail?id=2527484547","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527484547?lang=zh_cn&edition=fundamental","pubTime":"2025-04-15 12:03","pubTimestamp":1744689805,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU0797268264.HKD","07226","513600","LU1981816686.USD","HSCEI","09606","159843","LU1956131251.USD","BK1614","MHImain","81810","00981","02833","LU0052750758.USD","YANG","LU0918141705.HKD","BK1618","01458","01810","HSI","BK1521","HXXD.SI","LU0327786744.USD","LU0540923850.HKD","LU1868837565.USD","HSTECH","LU0700851271.USD","LU0499858438.USD","BK1163","BK1610","IE0034224299.USD","HSImain","LU2097828474.EUR","MCHmain","BK1549","LU1770036033.HKD","LU0593848301.USD","LU0359201612.USD","LU1023057109.AUD","LU0918141887.USD","BK1526","LU0348816934.USD","LU2148510915.USD","159582","HHImain","XIACY","000807.SH","LU0235996351.USD","688981","LU1961090484.USD"],"gpt_icon":0},{"id":"2527484571","title":"港股午评|恒生指数早盘涨0.19%       食品饮料股走高","url":"https://stock-news.laohu8.com/highlight/detail?id=2527484571","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527484571?lang=zh_cn&edition=fundamental","pubTime":"2025-04-15 12:00","pubTimestamp":1744689626,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，港股恒生指数涨0.19%，涨40点，报21457点；恒生科技指数跌0.91%。港股早盘成交1088亿港元。食品饮料股走高，市场风险偏好回落叠加内需预期提振，机构指食饮配置价值凸显。华润饮料涨4.95%，贸易冲突背景下内需重获重视，饮料业务有望保持高增速。名创优品早盘涨2.87%，机构称公司一季度同店环比改善，供应链多元化应对风险。报道称，这种豁免可能是短暂的。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1278697.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02460","513600","HSTECH","159843","000807.SH","HSI","02255","BK1241","BK1200","BK4614","HHImain","YANG","02833","09606","MCHmain"],"gpt_icon":1},{"id":"2527948252","title":"午评：港股恒指涨0.19% 科指跌0.91% 映恩生物涨超127%","url":"https://stock-news.laohu8.com/highlight/detail?id=2527948252","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527948252?lang=zh_cn&edition=fundamental","pubTime":"2025-04-15 12:00","pubTimestamp":1744689600,"startTime":"0","endTime":"0","summary":"　　4月15日消息，港股三大指数弱势震荡。截至午间收盘，恒生指数涨0.19%，报21457.61点，恒生科技指数跌0.91%，国企指数涨0.11%。盘面上，科网股涨跌不一，阿里巴巴涨超1%，网易、哔哩哔哩、快手、小米集团跌超1%；消费板块整体上涨，体育用品、食品、影视板块等齐涨，周黑鸭涨超8%；黄金股底部反弹，集海资源跌超8%；映恩生物上市首日一度大涨超130%。　　映恩生物上市首日一度大涨超130%。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-04-15/doc-inetfhrw8579228.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["HSI","513600","HHImain","MCHmain","MHImain","BK4614","HSImain","02833","YANG","HSTECH","09606"],"gpt_icon":1},{"id":"2527883364","title":"【新股IPO】映恩生物(09606) 布局ADC领域全球化商业模式  首日盘中暴涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2527883364","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527883364?lang=zh_cn&edition=fundamental","pubTime":"2025-04-15 11:13","pubTimestamp":1744686831,"startTime":"0","endTime":"0","summary":"金吾财讯|映恩生物(09606)上市首日盘中暴涨，最高至132.56%，每股222港元。早盘持续高位，截止发稿报208.8港元，涨幅达120.72%。昨日暗盘收盘亦大涨87.10%，报177.00港元，不计手续费，每手赚8240港元。据悉，映恩生物在ADC领域的全球化商业模式取得了显著的成效。从技术平台的构建到研发管线的布局，从全球授权合作到全球临床协同，映恩生物形成了一个完整的全球化商业闭环。已先后与BioNTech、百济神州、葛兰素史克、Avenzo等国际知名药企达成授权出海合作，交易总金额超过60亿美元，其中已经收到的预付款和商业化里程碑约5亿美元。","market":"fut","thumbnail":"https://static.szfiu.com/news/20220324/OWMzMDQ5MTY2NDM3ODU0ODM5.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20220324/OWMzMDQ5MTY2NDM3ODU0ODM5.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"5297752f2e4ee415e69380642a004984","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1957215","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC","BK4231","BK4080","09606"],"gpt_icon":0},{"id":"2527102646","title":"医健IPO解码｜从“魔法子弹”到资本新宠，映恩生物能否穿越市场周期？","url":"https://stock-news.laohu8.com/highlight/detail?id=2527102646","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527102646?lang=zh_cn&edition=fundamental","pubTime":"2025-04-15 10:31","pubTimestamp":1744684267,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者季媛媛上海报道作为一类新兴的大分子靶向药物，抗体偶联药物（ADC）结合了抗体的靶向能力和细胞毒性药物的杀伤效应，在肿瘤治疗领域展现出了卓越的疗效和巨大潜力，因而被誉为“魔法子弹”。与此同时，伴随着多款ADC药物的获批上市以及BD交易的不断涌现，ADC药物的商业化前景也得到了广泛验证，ADC已成为肿瘤药物研发领域的“璀璨明星”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202504153377154666.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504153377154666.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09606"],"gpt_icon":1},{"id":"2527285784","title":"映恩生物港股上市 募资15亿港元加速创新抗体药物研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2527285784","media":"iDoNews","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527285784?lang=zh_cn&edition=fundamental","pubTime":"2025-04-15 10:24","pubTimestamp":1744683842,"startTime":"0","endTime":"0","summary":"4月15日，专注于肿瘤及自身免疫疾病抗体药物研发的映恩生物正式登陆港交所，发行价为每股94.6港元。此次上市全球发售净筹资约15.13亿港元，资金将用于推动其创新药管线研发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041510413794d59a1a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"5297752f2e4ee415e69380642a004984","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041510413794d59a1a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09606","HSTECH","07226"],"gpt_icon":0},{"id":"2527410652","title":"ADC明星企业映恩生物登陆港交所，盘中涨幅高达116.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2527410652","media":"时代财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527410652?lang=zh_cn&edition=fundamental","pubTime":"2025-04-15 10:10","pubTimestamp":1744683017,"startTime":"0","endTime":"0","summary":"4月15日，ADC明星企业映恩生物-B（09606.HK）正式登陆港交所。截至发稿，映恩生物报205港元/股，涨幅116.7%。映恩生物IPO发行定价为94.6港元/股，认购情况火爆，募资总额约2.1亿美元（约合人民币15.4亿元），这是自2022年来募资规模最大的港股18A企业。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"5297752f2e4ee415e69380642a004984","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504153377128371.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4231","09606","ADC","BK4080"],"gpt_icon":0},{"id":"2527102312","title":"暴涨130%！映恩生物正式登陆港交所，市值超181亿港元，抗体偶联药物ADC领域全球领跑者","url":"https://stock-news.laohu8.com/highlight/detail?id=2527102312","media":"市场资讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527102312?lang=zh_cn&edition=fundamental","pubTime":"2025-04-15 09:52","pubTimestamp":1744681920,"startTime":"0","endTime":"0","summary":"　　映恩生物-B今日成功在港交所主板上市，Morgan Stanley、Jefferies以及CITIC Securities为联席保荐人。　　映恩生物是全球抗体偶联药物领域的关键领跑者，致力于为癌症和自身免疫性疾病等患者研发ADC创新药物。　　公司拥有自主研发的两款核心产品，即DB-1303/BNT323及DB-1311/BNT324。　　今日开盘，映恩生物涨130.44%，报218.00港元/股，市值181.32亿港元。　　截至2月19日，公司尚未获得任何候选药物的上市批准，亦未从产品销售中获得任何收入。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-04-15/doc-inetfhrt7419875.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["ADC","BK4231","09606","BK4080"],"gpt_icon":1},{"id":"1171661148","title":"新股首日 | 映恩生物-B涨幅扩大至130%，一手赚超12500港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1171661148","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171661148?lang=zh_cn&edition=fundamental","pubTime":"2025-04-15 09:51","pubTimestamp":1744681904,"startTime":"0","endTime":"0","summary":"4月15日，映恩生物-B上市首日盘初飙涨110%！此前获115.14倍认购，一手中签率80.01%。","market":"hk","thumbnail":"https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"5297752f2e4ee415e69380642a004984","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"映恩生物港股上市首日大涨130%，超额认购115倍彰显投资热情","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"gpt_icon":1},{"id":"2527504108","title":"映恩生物-B首挂上市 早盘高开逾115%","url":"https://stock-news.laohu8.com/highlight/detail?id=2527504108","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527504108?lang=zh_cn&edition=fundamental","pubTime":"2025-04-15 09:41","pubTimestamp":1744681260,"startTime":"0","endTime":"0","summary":"　　映恩生物-B首挂上市，公告显示，每股定价94.6港元，共发行1733.23万股股份，每手100股，所得款项净额约15.13亿港元。早盘高见218港元，截至发稿，股价上涨114.59%，现报203港元，成交额11.859亿港元。　　公开资料显示，映恩生物于2020年正式运营，是抗体偶联药物领域的全球领跑者。其中多项临床阶段的ADC，在17个国家230多个临床试验中心开展7项全球临床试验，已入组超过2000多名患者，50%患者来自海外。公司拥有自主研发的两款核心产品，即DB-1303/BNT323及DB-1311/BNT324。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"5297752f2e4ee415e69380642a004984","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggipo/2025-04-15/doc-inetfaka8079298.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09606"],"gpt_icon":1},{"id":"1108257735","title":"异动解读 | 映恩生物上市首日大涨114%，ADC创新药研发引爆投资热潮","url":"https://stock-news.laohu8.com/highlight/detail?id=1108257735","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108257735?lang=zh_cn&edition=fundamental","pubTime":"2025-04-15 09:32","pubTimestamp":1744680758,"startTime":"0","endTime":"0","summary":"今日，港股新上市公司映恩生物股价表现强劲，盘中大涨114.59%，引发市场广泛关注。该公司是一家专注于抗体偶联药物研发的创新生物制药企业，其上市首日的亮眼表现反映了投资者对其发展前景的看好。映恩生物此次IPO定价为每股94.6港元，发行1733.23万股股份。在昨日的暗盘交易中，映恩生物已上涨87.1%，为今日的强劲开盘奠定了基础。映恩生物成立于2020年，已迅速成为ADC领域的全球领先企业。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"5297752f2e4ee415e69380642a004984","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 映恩生物上市首日大涨114%，ADC创新药研发引爆投资热潮","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09606"],"gpt_icon":1}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":67,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09606\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09606\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09606\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09606\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09606","date":"2025-04-30","current":-15.806523,"percent":0.6,"low":-17.183112,"twenty":-16.756996,"median":-15.846935,"eighty":-14.905978,"high":-7.368305,"avg":-15.17124,"sd":2.625448,"marketCap":17719522633},"quantilePoints":[{"date":"2025-04-17","current":-14.905978,"twenty":-15.065639,"median":-14.442293,"eighty":-11.334487,"marketCap":16635152800},{"date":"2025-04-25","current":-15.846935,"twenty":-16.770434,"median":-15.576033,"eighty":-14.349556,"marketCap":17719522633},{"date":"2025-04-30","current":-15.806523,"twenty":-16.756996,"median":-15.846935,"eighty":-14.905978,"marketCap":17719522633}],"updateTime":1746106671315}}}